1   **TITLE PAGE**
2
3   **Title:** Predicting future ocular *Chlamydia trachomatis* infection prevalence using serological,
4   clinical, molecular, and geospatial data
5

6   **Authors:** Christine Tedijanto[1], Solomon Aragie[2], Zerihun Tadesse[2], Mahteme Haile[3], Taye
7   Zeru[3], Scott D. Nash[4], Dionna M. Wittberg[1], Sarah Gwyn[5], Diana L. Martin[5], Hugh J.W.
8   Sturrock[6], Thomas M. Lietman[1,7,8,9], Jeremy D. Keenan[1,7], Benjamin F. Arnold[1,7]
9
Author affiliations: [1]Francis I. Proctor Foundation, University of California, San Francisco, CA
94143; [2]The Carter Center Ethiopia, Addis Ababa, Ethiopia; [3]Amhara Public Health Institute,
Bahir Dar, Ethiopia; [4]The Carter Center, Atlanta, Georgia; [5]Division of Parasitic Diseases and
Malaria, Centers for Disease Control and Prevention, Atlanta, GA 30333; [6]Locational, Poole,
UK; [7]Department of Ophthalmology, University of California, San Francisco, CA 94143;
[8]Department of Epidemiology and Biostatistics, University of California, San Francisco, CA
94143; [9]Institute for Global Health Sciences, University of California, San Francisco, CA 94143;
17
18   **Corresponding author:** Christine Tedijanto
19   *Email:* christine.tedijanto@ucsf.edu
20   *Address:* F.I. Proctor Foundation, 490 Illinois Street, San Francisco, CA 94107

21
22   **Keywords:** trachoma, epidemiology, serology, prediction, geospatial

23 **ABSTRACT**
24
Trachoma is an infectious disease characterized by repeated exposures to *Chlamydia*
trachomatis (*Ct*) that may ultimately lead to blindness. District-level estimates of clinical disease
are currently used to guide control programs. However, clinical trachoma is a subjective
indicator. Serological markers present an objective, scalable alternative for monitoring and
targeting of more intensive control efforts. We hypothesized that IgG seroprevalence in
combination with geospatial layers, machine learning, and model-based geostatistics would be
able to accurately predict future community-level ocular *Ct* infections detected by PCR. Among
40 communities in the hyperendemic Amhara region of Ethiopia, median *Ct* infection prevalence
among children 0-5 years old increased from 6% at enrollment to 29% at month 36.
Seroprevalence was the strongest concurrent predictor of infection prevalence at month 36
among children 0-5 years old (cross-validated R^2 = 0.75, 95% CI: 0.58-0.85), though predictive
performance declined substantially with increasing temporal lag between predictor and outcome
measurements. Geospatial variables, a spatial Gaussian process, and stacked ensemble
machine learning did not meaningfully improve predictions. Serological markers among children
0-5 years old may be a promising programmatic tool for identifying communities with high levels
of active ocular *Ct* infections, but accurate, future prediction in the context of changing
transmission remains a challenge.

42
43 **INTRODUCTION**
44
Trachoma, caused by ocular infection with the bacterium *Chlamydia trachomatis* (*Ct*), is a
leading infectious cause of blindness worldwide (1) and has been targeted for elimination as a
public health problem by 2030 (2). The World Health Organization's SAFE strategy (Surgery,
Antibiotics, Facial cleanliness, and Environmental improvement) has been successful in
countries across Asia and the Middle East, achieving elimination as a public health problem in
many cases (2). Yet, trachoma is a persistent challenge in pockets of Africa, including some
areas of Ethiopia that remain hyperendemic despite over 10 years of control activities (3). The
ability to efficiently identify potential areas of ongoing transmission for follow-up surveys and
more intensive interventions is crucial for the trachoma endgame.
54
Trachoma elimination programs are currently guided by estimates of clinical disease markers,
including trachomatous inflammation — follicular (TF), in evaluation units (EUs) of 100,000-
250,000 people (4). Evidence of trachoma clusters at the village- or sub-village level throughout
Africa (5–10) suggest that aggregate estimates may mask heterogeneity in infection: high-
transmission villages may be missed by sampling design or their signal may be "washed out" in
EU-level averages. Fine-scale estimates of trachoma could facilitate targeted allocation of
limited resources to communities with the highest burden (11) and reduce unnecessary
antibiotic use and subsequent selection for antibiotic resistance (12).
63
Mass drug administration (MDA) of azithromycin is currently recommended for EUs with TF
prevalence above 5% among children aged 1-9 years old (2). Clinical disease states are
relevant signals of progression towards conjunctival scarring and ultimately blindness (1) but are

subject to misclassification, even by experienced graders (13). Immunoglobulin G (IgG)
antibody responses to Pgp3 and CT694 antigens are a more objective alternative and have
been identified as sensitive, specific, and durable indicators of past ocular *Ct* infection (14, 15).
In addition, dried blood spot specimens used to assess serological markers are easy to collect,
and *Ct* antigens can be included in multiplexed, integrated serosurveillance platforms to
simultaneously and cost-effectively monitor numerous pathogens (16).
73
Thus far, efforts to predict future trachoma prevalence at the village and district level have had
modest success (17, 18) but have not considered serology or recent advances in machine
learning and geostatistics that may facilitate fine-scale prediction. We hypothesized that models
incorporating trachoma indicators (clinical disease, ocular *Ct* infection identified by polymerase
chain reaction (PCR), and IgG response to *Ct* antigens), remotely sensed geospatial layers, and
spatial structure would accurately predict future community-level *Ct* infection prevalence. We
also hypothesized that seroprevalence would be a more accurate and stable predictor of *Ct*
infections compared to clinical disease and that communities with high levels of infection would
be geographically clustered in stable foci of transmission ("hotspots"). We tested our
hypotheses using data from the WASH Upgrades for Health in Amhara (WUHA) randomized
controlled trial (NCT02754583) (19).
85
86 **RESULTS**
87
Study population and setting. WUHA was a randomized controlled trial designed to evaluate
the impact of a comprehensive water, sanitation, and hygiene (WASH) intervention on ocular *Ct*
infection. The trial was conducted in forty communities in a dry, mountainous region of the Wag
Hemra Zone of Amhara, Ethiopia (**Figure 1**). MDA was conducted for seven consecutive years
in the study communities before the study began but was suspended for the duration of the trial.
Baseline measurements were collected in December 2015 (month 0), and follow-up visits
occurred annually for three years thereafter (months 12, 24, and 36). Clinical, serological, and
molecular trachoma indicators were measured among randomly sampled children ages 0-9
years old at each visit. Data were combined across the two intervention arms for this secondary
analysis as no difference was observed for the primary endpoint of ocular *Ct* infection at the end
of the study period [manuscript under review].

Figure 1. Map of study area. Inset (top right) highlights the Amhara Region (gray shading) of Ethiopia
and the study area (black rectangle). Forty communities from three woredas (administrative level 3) in
Amhara were included in the WUHA trial.
102

103
104
Approximately thirty children from two age groups (0-5 years old and 6-9 years old) were
randomly sampled from each community at baseline and follow-up visits. The number of
children evaluated differed slightly for each trachoma indicator (**Table S1**). Over the three-year
study period, ocular *Ct* infection prevalence, as measured by PCR, increased substantially in
both age groups (**Table 1**). Throughout this analysis, clinical disease was defined as diagnosis
with either trachoma inflammation - follicular (TF), the presence of five or more follicles on the
upper eyelid, or trachoma inflammation - intense (TI), a condition characterized by inflammatory
thickening of the upper eyelid (20). Levels of clinical disease fluctuated with time but remained
fairly consistent with baseline levels. Seropositivity, defined as antibody response above pre-
determined cut-offs for both Pgp3 and CT694 antigens, increased gradually among 0–5-year-
olds. Antibodies were not measured among 6–9-year-olds at months 12 and 24 but were similar
between study arms at months 0 and 36. Results were similar when seroprevalence was
assessed for each antigen separately (**Table S2**).

Table 1. Community-level prevalence of trachoma across 40 study communities by indicator, age
group and month of follow-up visit.
120

	Median prevalence (%) (IQR), 0–5-year-olds				Median prevalence (%) (IQR), 6–9-year-olds			
Month	n[1]	PCR[2]	Clinical TF/TI[3]	Serology	n[1]	PCR[2]	Clinical TF/TI[3]	Serology[4]
0	1,269	5.6 (2.9-18.1)	62.9 (51.0-72.5)	25.0 (10.1-34.8)	1,135	3.5 (0.0-13.9)	40.3 (25.9-54.9)	49.2 (29.8-60.2)
12	1,162	19.1 (6.6-30.2)	50.8 (40.6-61.1)	29.7 (15.6-40.2)	1,092	10.9 (5.7-17.4)	21.3 (14.3-27.8)	-
24	1,214	27.4 (11.6-34.3)	67.5 (55.5-77.4)	33.3 (20.5-39.0)	1,208	19.9 (9.7-34.2)	45.1 (29.4-53.4)	-
36	1,192	29.3 (16.2-46.8)	56.7 (45.2-64.3)	33.3 (23.5-42.3)	1,218	21.7 (15.2-38.2)	38.2 (30.1-53.6)	50.8 (28.9-65.4)

121 *1 Number of children tested for any indicator across all study communities*
122 *2 Polymerase chain reaction*
123 *3 Trachomatous inflammation - follicular / trachomatous inflammation - intense*
124 *4 Serology was not measured for a random sample of 6–9-year-olds at months 12 and 24*
125

Active ocular infection was more common in the western and northern regions of the study area
(**Figure 2A**); seroprevalence and clinical disease were similarly distributed in space (**Figure
S1A, Figure S2A**). Based on empirical variograms (**Figure 2B**) and Moran's I (**Figure 2C**),
there was weak spatial structure in community-level Ct PCR prevalence that increased slightly
over the study period; serology and clinical indicators also did not display clear spatial structure
over the study area (**Figure S1B-C**, **Figure S2B-C**).

Figure 2. (A) Predicted surface, (B) variograms, and (C) Moran's I for PCR-confirmed ocular *C. trachomatis* infection prevalence among 0–5-year-olds at each study month. Maps display prevalence for 40 study communities at each follow-up visit, spatially interpolated over the convex hull using kriging. Variograms capture similarity between community-level prevalence measurements as a function of distance between community pairs (in km), with smaller semivariance values representing increased similarity. Exponential (magenta) and Matérn (green) models were fit to each empirical variogram, and the effective range (dashed vertical line) is defined as the distance at which the fitted model reaches 95% of the sill. The Monte Carlo envelope (gray shading) displays pointwise 95% coverage of 1000 permutations, representing a null distribution. Moran's I was calculated over 1000 permutations (gray bars, with observed value represented by red line), and a permutation-based p-value was calculated.

Comparisons between serological, clinical, and molecular trachoma indicators.
Seroprevalence demonstrated a stronger rank-preserving relationship, as measured by the
Spearman correlation, with contemporaneous PCR prevalence than clinical disease for both
age groups (**Figure 3A-B**). At baseline, immediately following seven years of MDA, the
correlations between trachoma indicators were more pronounced among younger children,
potentially reflecting lower transmission in the presence of MDA and saturation in
seroprevalence due to durable antibody responses among older children. In a longitudinal
cohort nested within the study, children who were seropositive at any survey were very likely to
be seropositive one year later (**Figure S4**). Similar saturation dynamics may be at play for
clinical trachoma, which has been shown to resolve slowly among children (21). By month 36,
when infections were higher across the study area (**Table 1**), correlations between trachoma
indicators were similar across age groups (**Figure 3A-B**). Rank-preserving relationships
between indicators at each time point and month 36 PCR prevalence were stronger for more
proximate measurements, and this increase was more pronounced for PCR compared to clinical
trachoma or serology (**Figure 3C**).
159
Figure 3. Correlations between trachoma indicators by age group and over time. Panels display
Spearman rank correlations between (A) community-level seroprevalence and PCR prevalence at study
months 0 and 36, (B) clinical trachoma prevalence and PCR prevalence at months 0 and 36, and (C)
PCR prevalence at month 36 and trachoma indicators measured at earlier months across 40 study
communities. Correlations are shown separately for 0–5-year-olds (green) and 6–9-year-olds (purple),
and 95% confidence intervals were estimated from 1000 bootstrap samples. Serology data was not
collected for a random sample of 6–9-year-olds at months 12 and 24.
167

Concurrent and forward prediction of PCR prevalence. We predicted community-level
infection prevalence using a range of model specifications and conducted spatial 10-fold cross-
validation (CV) with 15x15 km blocks (22) to assess predictive performance using CV R^2 and
root-mean-square-error (RMSE) (details in **Materials and Methods**). **Figure 4** presents results
for models predicting PCR prevalence at month 36. "Concurrent" predictions utilized trachoma
indicators measured at month 36 and/or geospatial variables measured over the preceding year
(2018), while "forward" predictions used covariates measured 12, 24, or 36 months in the past.
Seroprevalence was the single strongest concurrent predictor of month 36 community-level
PCR prevalence (CV R^2: 0.75, 95% confidence interval (CI): 0.58-0.85, CV RMSE: 0.10),
substantially outperforming clinical trachoma prevalence (CV R^2: 0.37, 95% CI: 0.08-0.56, CV
RMSE: 0.16) (**Figure 4**). When predicting 12 months into the future, all trachoma indicators
performed moderately well, but predictive performance declined for longer time horizons across
all model specifications. No model that we assessed had a CV R^2 significantly different from 0
(equivalent to an intercept-only or mean-only model) when predicting PCR prevalence 24
months or more into the future.
184
As anticipated by the weak spatial dependence in PCR prevalence (**Figure 2**), incorporation of
a Gaussian process with a Matérn covariance function did not improve predictions. In addition,
LASSO-selected geospatial features (night light radiance and daily precipitation averaged over
the preceding 12 months) (**Figure S5**) and a stacked ensemble approach leveraging five base
models did not meaningfully improve CV R^2 or CV RMSE compared to simpler models. Results
were similar for models predicting PCR prevalence at each time point and pooled over all time
points (**Figure S6**).
192
Figure 4. Cross-validated R^2 for models predicting month 36 community-level PCR prevalence
among 0–5-year-olds. Cross-validated coefficient of determination (R^2), 95% influence-function-based
confidence interval, and cross-validated root-mean-square error (RMSE, text label) are shown for each
model specification. Logistic regression was used for all models with the exception of the stacked
ensemble (gray). Blocks of size 15x15km were used for 10-fold spatial cross-validation.

Efficient identification of high-burden communities. A complementary task to prediction is
identifying communities with the highest infection burden, defined here as the number of *Ct*
infections among 0–5-year-olds at a given time. To address variability in sample size, the
number of *Ct* infections in each community was scaled to represent a sample of 30 individuals.
At month 36, 80% of *Ct* infections were concentrated in just over half of the communities
(23/40), and ordering communities by cross-validated concurrent predictions using
seroprevalence identified infections more efficiently (i.e. in fewer communities, 25/40) than
ordering them by predictions using clinical trachoma (27/40) (**Figure 5**). Performance declined
when using predictors measured 12 months in the past, and communities ranked by predictors
measured 24 and 36 months in the past could not identify high-burden communities based on
PCR infections at month 36 better than chance. The distinction between models was greater at
month 0 when 80% of *Ct* infections were concentrated in just the top 15 of 40 (38%) of
communities (**Figure S9**).
212
Figure 5. Cumulative proportion of *C. trachomatis* infections at month 36 identified by concurrent
and forward prediction models. Dashed lines indicate the point at which the cumulative proportion of
identified *Ct* infections at month 36, scaled to represent a sample of 30 individuals per community,
surpassed 80%. The black line in each facet represents the optimal ordering of scaled PCR infections at
month 36. To simulate a null distribution, we estimated the cumulative proportion of infections identified
for 1000 random orderings of the 40 communities and plotted the 95% pointwise envelope (gray shading).
For concurrent and 24-month-forward predictions, models using serology only and PCR only,
respectively, performed equally well to a model using all trachoma indicators, geospatial features, a
Matérn covariance, and ensemble machine learning; vertical lines were offset slightly for visibility.
222

223
224
225   **DISCUSSION**
226
We conducted a comprehensive study of repeated cross-sectional measurements of clinical
trachoma, PCR-positive ocular *Ct* infections, and serological responses to *Ct* antigens over
three years in 40 communities in the hyperendemic Amhara region of Ethiopia. In the absence
of MDA during the study, active *Ct* infections surged and became increasingly dispersed across
study communities. Based on empirical variograms and Moran's I, we observed weak evidence
for global spatial clustering in trachoma indicators over the study region. Seroprevalence among
children 0-5 years old aligned closely with PCR prevalence measured at the same time,

highlighting the potential for serosurveillance as a monitoring tool that corresponds well with
levels of active infection and is potentially easier to measure (23). Predictive performance of all
models declined with increasing temporal lag between outcome and predictor measurements. In
this setting, remotely sensed demographic, socioeconomic, and environmental geospatial
layers, a spatial Gaussian process with Matérn covariance, and stacked ensemble machine
learning did not meaningfully improve predictive performance compared to models using only
trachoma indicators.
241
Identifying potential future trachoma hotspots is notoriously challenging and sometimes termed
"chasing ghosts" by trachoma programs (17). Our results underscore the difficulty of predicting
community-level *Ct* infection prevalence even a year into the future, at least in the context of
increasing transmission in the absence of MDA. Furthermore, our "forward prediction" models
were trained on infection outcomes from the desired prediction time point and thus were
potentially more optimistic than true "forecasting" models trained solely on historical data. Prior
efforts to forecast district-level TF (18) and village-level PCR prevalence (17) have explored
mechanistic and statistical models and observed modest performance, with one investigation
concluding that models with the highest uncertainty resulted in the best predictive performance
(17). It remains unclear why future prediction of trachoma presents such a difficult challenge,
though likely contributing factors include the stochasticity of rare events especially in near-
elimination settings (24), biological unknowns in the complex natural history of trachoma (25),
and the extended duration between survey measurements (often 6 months or greater). Models
for other neglected tropical diseases have achieved some success in future prediction at the
sub-district level, though often capitalizing on larger datasets. For example, a recent study
developed models with over 80% accuracy for prediction of *Schistosoma mansoni* persistent
hotspots (defined as failure of a village to reduce infection prevalence and/or intensity by
specific thresholds) up to two years in the future in the context of decreasing prevalence (26). In
a setting with fairly stable transmission, a sub-district-level study for visceral leishmaniasis
reported 85.7% coverage of four-month-ahead 25-75% prediction intervals for case counts (27).
262
Our investigation builds upon an existing body of work characterizing the dynamics between
clinical, serological, and molecular trachoma indicators. Reports at the district, village, and
individual level have established that relatively high levels of clinical trachoma or ocular
infections tend to correspond to higher seroprevalence and/or seroconversion rates (14, 28–31);
post-elimination settings have been of particular interest, with populations often displaying little
to no antibody response (15, 32–37). Our findings align with earlier studies that showed clinical
trachoma is more strongly correlated with infection prevalence in populations with ongoing
transmission compared to populations in which transmission has been suppressed by MDA
(38–40); also in agreement with prior findings, we observed that TI was slightly, but not
significantly, more closely correlated with infection prevalence compared to TF immediately
following MDA (**Figure S10**) (41). We additionally found that seroprevalence among children 0-9
years old was more closely aligned with infection prevalence than clinical trachoma in both
contexts. Moreover, we found that seroprevalence was more strongly correlated with PCR
prevalence among children 0-5 years old compared to children 6-9 years old, especially in the

context of recent MDA at month 0. This result supports a focus on children 0-5 years old as a
key sentinel population for trachoma serosurveillance.
279
In general, we did not observe strong evidence of global spatial autocorrelation for trachoma
indicators over the study region, though spatial structure in PCR prevalence appeared to
increase slightly over the study period. A prior analysis over the entire Amhara region reported
evidence of spatial autocorrelation in TF between villages within 25km bands (10), and another
study of TF and TI in Southern Sudan detected residual spatial structure between villages at
approximately 8 km, after adjusting for age, sex, rainfall, and land cover (42). A larger number of
existing studies have characterized spatial autocorrelation at a fairly small scale. Studies using
household-level information identified spatial clustering at less than 2 km for bacterial load (6,
9), ocular infection (8, 9), and clinical disease (43). Our ability to detect spatial structure may
have been limited by the geographic distribution of the communities, which was determined by
the main trial objectives rather than optimized for estimation of spatial model parameters, which
often requires points fairly close to one another (44). In our study, only 26 (out of 780) pairs of
study communities were within 5 km of one another leading to wide uncertainty at small ranges
and hindering our ability to assess fine-scale spatial clustering.
294
In addition to rainfall and land cover, studies have reported associations between clinical
trachoma and distance to water source (10, 45–47), temperature (7, 46, 48), altitude (46, 48–
51), markers of socioeconomic status (7, 10, 45, 47, 51, 52), and markers of personal or
household hygiene, such as facial cleanliness (7, 10, 45, 47, 52–59). Fewer studies have
examined *Ct* infections identified by PCR, but associations reported were generally similar (52,
59, 60). Using LASSO to down-select geospatial features, we included night light radiance
(often a proxy for socioeconomic activity (61)) and precipitation in prediction models. However,
these features were unable to predict infection prevalence better than an intercept-only model.
Predictive power of geospatial variables may have been limited by relative homogeneity across
the study area, and the relatively small number of communities likely limited the predictive
performance of all models.
306
Finally, our analysis focused on a hyperendemic region with increasing trachoma transmission
in the absence of MDA and may not generalize to lower transmission settings. Ethiopia's
Amhara region presents a particularly stubborn elimination challenge, as seven consecutive
years of MDA were unable to sustain control before the start of this study. It is unclear whether
prediction would be more or less challenging in the context of low transmission; we may expect
more predictability in a "steady state" environment, but stochasticity is also a defining
characteristic of near-elimination disease dynamics (24). As an additional sensitivity analysis,
we included survey month as a covariate to assess potential benefits of repeated sampling in
the context of changing transmission and found only a modest improvement in predictive
performance (**Figure S11**).
317
Conclusions. Serological markers among children 0-5 years old may be well-suited for
community-level trachoma monitoring given their objectivity, durability, relative ease of
collection, and strong correlation with ocular *Ct* infection prevalence. While seroprevalence and

clinical trachoma were both correlated with infection prevalence in the midst of high
transmission in the absence of MDA, only seroprevalence was strongly associated with
community-level infections in the context of suppressed transmission directly following MDA.
Accurate, future prediction of community-level *Ct* infection prevalence in settings with unstable
transmission remains an open challenge.
326
327   **MATERIALS AND METHODS**
328
Data collection. This work was designed as a secondary analysis of data from the WASH
Upgrades for Health in Amhara (WUHA) community-randomized trial, one of the trials in the
Sanitation, Water, and Instruction in Face-Washing for Trachoma (SWIFT) (NCT02754583)
series. Details of study methodology and implementation are described in the published protocol
(19). WUHA was conducted in the Gazgibella, Sekota Zuria (i.e. Sekota) and Sekota Ketema
(i.e. Sekota town) woredas of the Wag Hemra Zone in Amhara, Ethiopia. Forty communities
were randomized in a 1:1 ratio to receive a comprehensive Water, Sanitation, and Hygiene
(WASH) package at baseline or at completion of the study. Mass administration of azithromycin
occurred for seven consecutive years (May 2009 to June 2015, with supplemental
administration in October 2014) prior to the start of the study but was suspended in all study
communities for the duration of the WUHA trial.
340
Trachoma indicators were measured in each study community at baseline and three annual
monitoring visits. Approximately one month prior to each monitoring visit, a census was taken to
enumerate individuals living in each study community. The baseline census was conducted in
December 2015. At each visit, thirty individuals in three age groups (0-5, 6-9, 10+) were
randomly selected from each community for monitoring; this analysis focused on children aged
0-9 years old. Per the trial design, not all trachoma indicators were measured in all age groups
at each time point; only children 0-5 years old were tested for clinical, serological, and molecular
outcomes at all visits. At the end of WUHA, no difference in the primary endpoint of community-
level ocular *Ct* infection among 0–5-year-olds was observed between intervention arms
[manuscript under review]. As a result, we combined information across arms for this analysis.
351
352   ***Measurement and definition of trachoma indicators.*** We analyzed age-group-specific
353   community-level prevalence of three trachoma indicators: clinical disease, active ocular *Ct*
354   infection detected by polymerase chain reaction (PCR), and IgG response to Pgp3 and CT694
355   antigens.
356
357   Trained trachoma graders used a pair of 2.5X loupes and a flashlight to assess the everted right
358   superior tarsal conjunctiva for the presence of trachomatous inflammation - follicular (TF) or
359   trachomatous inflammation - intense (TI) according to the WHO grading system (62). An
360   individual was considered positive for clinical trachoma if either TF or TI was detected.
361
Conjunctival swabs were collected and tested in the study laboratory at the Amhara Public
Health Institute in Bahir Dar, Ethiopia with the Abbott RealTime assay (automated Abbott
m2000 System), which is highly sensitive and specific for *Ct* (63, 64). Groups of five samples,

stratified by community and age group, were pooled for testing, and community-level *Ct*
infection prevalence was estimated from pooled results using a maximum likelihood approach
(65). Certain pools were selected for individual-level PCR testing based on pooled prevalence
and other characteristics.
369
To measure antibody response, field staff lanced the index finger of each individual and
collected blood onto TropBio filter paper. Samples were tested at the US Centers for Disease
Control on a multiplex bead assay on the Luminex platform for antibodies to two recombinant
antigens (Pgp3, CT694) that measure previous exposure to *C. trachomatis* (14, 15, 66).
Seropositivity thresholds were defined as median fluorescence intensity minus background
(MFI-bg) of 1113 for Pgp3 and 337 for CT694 using an ROC cutoff from reference samples (37).
Individuals who were seropositive with respect to both antigens were considered seropositive
for the main analysis; descriptive results were similar when considering either antigen
separately (**Table S2, Figure S3**).Descriptive analysis of trachoma indicators. Spearman rank
correlation coefficients were calculated for pairwise combinations of trachoma indicators by age
group and follow-up visit. Correlations were also calculated between PCR prevalence at month
36 and serological, molecular, and clinical prevalence at each preceding time point to observe
changes in correlation with increasing temporal lag between measurements. 95% confidence
intervals were estimated from 1000 bootstrap samples.
384
Descriptive spatial analysis. Administrative boundaries for Ethiopia were downloaded from the
Humanitarian Data Exchange (67). Spatially interpolated maps for each trachoma indicator at
each time point were generated using a simple kriging model including latitude, longitude, and a
Matérn covariance. We estimated empirical variograms after removing linear spatial trends for
distances up to 33.3 km (half of the maximum distance between any two study communities)
and fit exponential and Matérn models; for stability, we required bins to contain ten or more
pairs of communities. The effective, or practical, range was defined as the distance at which the
fitted model reached 95% of the sill. We compared the observed variograms to a 95% pointwise
envelope based on 1000 Monte Carlo simulations; for each simulation, prevalence residuals
were permuted while holding coordinates fixed and the empirical variogram was recalculated
(68). We also calculated Moran's I, a measure of global spatial autocorrelation, over 1000
permutations of the prevalence values and estimated a p-value based on permutations resulting
in a Moran's I greater than or equal to the observed value.
398
Predictive model selection. Prediction models were limited to children 0-5 years old due to
availability of all trachoma indicators for this age range at all time points. We developed several
candidate models using baseline data only, with the analysis team masked to any future
measurements. A wide range of publicly available environmental (69–73), demographic (74),
and socioeconomic (75–77) variables were explored based on prior associations with trachoma
or other infectious diseases (Table S3). When possible, features were extracted and aggregated
using Google Earth Engine (78), and means were used for spatial and temporal aggregation
unless otherwise specified in Table S3. All features were aggregated to a grid resolution of 2.5
arc minutes (approximately 4.5 km at the median latitude of the study area) based on the lowest
resolution dataset (TerraClimate) and reprojected to WGS84. Each community was assigned to

the grid cell containing its household-weighted geographic centroid, defined as the median
latitude and longitude across all households in the community.
411
Models were built using predictor variables measured over the same ("concurrent") and prior
("forward predictions") time periods. Time-varying features were summarized based on calendar
year, with 2015 data considered "concurrent" with month 0 trachoma indicators and so on.
Time-varying features were first aggregated by month and then summarized based on recency
relative to the time of monitoring (e.g. last 1 month or December of the calendar year, last 2
months, up to 12 months). To reduce collinearity, we evaluated pairwise Pearson correlation
coefficients between temporal summaries of the same variable and dropped the summary over
fewer months for pairs with correlation over 0.9.
420
During preliminary model development with baseline data, we observed that a large number of
predictor variables led to overfitting and unstable model performance due to the relatively small
number of communities. As a result, logistic LASSO regression was used to identify a restricted
set of geospatial features to include in the final prediction models. Night light radiance and daily
precipitation averaged over the preceding 12 months were selected from a model using
concurrently measured predictors and outcomes across all follow-up visits.
427
428   Logistic regression models of the following form were used as base prediction models:
429

430    $$logit(p_{cm}) = \alpha + \sum_p \beta_{np} x_{cnp} + S(\text{latitude}_c, \text{longitude}_c)$$

431
432   where p_{cm} represents PCR prevalence for study community c at month m, α is the model
433   intercept, and $x_{cn1}...x_{cnp}$ denote covariates with coefficients β measured at time n, where $n = m$
434   for concurrent predictions and $n = m - k$ for predictions k months forward. Extended models also
435   included a Gaussian process with Matérn covariance function (79) to capture residual spatial
436   structure, represented by the S function dependent on latitude and longitude of the community.
437
As an extension of our prediction models, we also explored stacked ensemble machine
learning, also known as stacked regression (80) or stacked generalization (81). Stacked
ensembles combine predictions from multiple 'Level 0' models using a 'Level 1' model, also
called the superlearner or metalearner (82). Ensembles are theoretically guaranteed to perform
as well as or better than any single member of their library (80, 82). Our 'Level 0' learners
included logistic regression, generalized additive models (83), random forest (84), extreme
gradient boosting (85), and multivariate adaptive regression splines (86). This set of models,
including parametric, semi-parametric, and tree-based methods, was selected to ensure
diversity in approach; outcome specification also varied (e.g. binomial, quasibinomial,
continuous) based on requirements of the learner. Logistic regression with a Matérn covariance
was used as 'Level 1' superlearner for the baseline analysis; different superlearner models,
including logistic regression without a Matérn covariance and non-negative linear least squares
with and without normalized (convex combination) coefficients, resulted in similar predictive
performance (**Figure S7**).
452

Predictive model assessment. We conducted 10-fold cross-validation to assess predictive
performance. Spatial autocorrelation can violate the independence assumption between training
and validation sets in cross-validation and lead to overly optimistic estimates of predictive power
(22, 87). Therefore, we partitioned the study area into 12 15x15km blocks, each containing 1-8
spatially proximate communities. Communities in the same block were assigned to the same
validation set, with some sets consisting of more than one block. This approach decreases
spatial dependence between training and validation sets in the same fold and simulates
prediction in a new, but geographically proximate, area. We observed consistent results in
sensitivity analyses using leave-one-out cross-validation, random cross-validation folds, and
spatial blocks of 5x5 km and 20x20 km (**Figure S8**), perhaps reflecting the weak spatial
autocorrelation observed in this dataset (**Figure 2**). Predictive performance was assessed using
cross-validated root-mean-square-error (RMSE) and R^2 (88), where R^2 was calculated as:

$$1 - \frac{\sum_c (p_{cm} - \hat{p}_{cm})^2}{\sum_c (p_{cm} - \bar{p}_{cm})^2}$$

466
467

468 95% confidence intervals for R^2 were estimated using the influence function (89, 90).
469 Communities received equal weight in all validation metrics.
470

Acknowledgements and funding sources. We would like to thank the WUHA study
participants and field team without whom this research would not be possible. This work was
supported by the National Institute of Allergy and Infectious Diseases (R03 AI147128 to BFA)
and the National Eye Institute (U10 EY023939 to JDK). This work was also made possible in
part by an Unrestricted Grant from Research to Prevent Blindness. We would also like to thank
Abbott for its donation of the m2000 RealTime molecular diagnostics system and consumables.
477

478 ***Competing interest statement.*** The authors have no competing interests to report. The
479 findings and conclusions in this article are those of the authors and do not necessarily represent
480 the official position of the Centers for Disease Control and Prevention. Use of trade names is for
481 identification only and does not imply endorsement by the Public Health Service or by the U.S.
482 Department of Health and Human Services.
483
Data and availability. The pre-specified statistical analysis plan will be made available on Open
Science Framework (https://osf.io). The main R packages used for this analysis were *automap*
(variograms) (91), *rgee* (Google Earth Engine) (92), *glmnet* (feature selection) (93), *spaMM*
(regression with spatial Gaussian process) (94), *sl3* (stacked ensemble) (95), and *blockCV*
(spatial cross-validation) (96). De-identified data and code to replicate this work will be made
available on Github (https://github.com/ctedijanto/swift-spatial-prediction). All analysis was
conducted in R Version 4.0.2 ("Taking Off Again") (97).
491
Author contributions:
Conceptualization: CT, BFA
Data curation: CT, JDK
Formal analysis: CT
Funding acquisition: BFA, JDK
Investigation: CT, BFA
Methodology: CT, HJWS, BFA
Project administration: CT
Resources: SG, DLM, SDN
Software: CT
Supervision: TML, JDK, BFA
Validation: CT
Visualization: CT
Writing - original draft preparation: CT, BFA
Writing - review & editing: All authors

REFERENCES

1. H. R. Taylor, M. J. Burton, D. Haddad, S. West, H. Wright, Trachoma. *The Lancet* **384**, 2142–2152 (2014).
2. World Health Organization, "WHO Alliance for the Global Elimination of Trachoma by 2020: progress report, 2019" (World Health Organization, 2020).
3. E. Sata, *et al.*, Twelve-Year Longitudinal Trends in Trachoma Prevalence among Children Aged 1–9 Years in Amhara, Ethiopia, 2007–2019. *Am. J. Trop. Med. Hyg.* **104**, 1278–1289 (2021).
4. World Health Organization, "Validation of elimination of trachoma as a public health problem" (World Health Organization, 2016) (April 6, 2021).
5. R. Bailey, C. Osmond, D. C. W. Mabey, H. C. Whittle, M. E. Ward, Analysis of the Household Distribution of Trachoma in a Gambian Village Using a Monte Carlo Simulation Procedure. *Int. J. Epidemiol.* **18**, 944–951 (1989).
6. A. T. Broman, K. Shum, B. Munoz, D. D. Duncan, S. K. West, Spatial Clustering of Ocular Chlamydial Infection over Time following Treatment, among Households in a Village in Tanzania. *Investig. Opthalmology Vis. Sci.* **47**, 99 (2006).
7. M. Hägi, *et al.*, Active Trachoma among Children in Mali: Clustering and Environmental Risk Factors. *PLoS Negl. Trop. Dis.* **4**, e583 (2010).
8. J. Yohannan, *et al.*, Geospatial Distribution and Clustering of *Chlamydia trachomatis* in Communities Undergoing Mass Azithromycin Treatment. *Investig. Opthalmology Vis. Sci.* **55**, 4144 (2014).
9. A. Last, *et al.*, Spatial clustering of high load ocular Chlamydia trachomatis infection in trachoma: a cross-sectional population-based study. *Pathog. Dis.* **75** (2017).
10. F. M. Altherr, *et al.*, Associations between Water, Sanitation and Hygiene (WASH) and trachoma clustering at aggregate spatial scales, Amhara, Ethiopia. *Parasit. Vectors* **12**, 540 (2019).
11. S. F. Dowell, D. Blazes, S. Desmond-Hellmann, Four steps to precision public health. *Nature* **540**, 189–191 (2016).
12. K. S. O'Brien, *et al.*, Antimicrobial resistance following mass azithromycin distribution for trachoma: a systematic review. *Lancet Infect. Dis.* **19**, e14–e25 (2019).
13. S. Gebresillasie, *et al.*, Inter-Rater Agreement between Trachoma Graders: Comparison of Grades Given in Field Conditions versus Grades from Photographic Review. *Ophthalmic Epidemiol.* **22**, 162–169 (2015).
14. E. B. Goodhew, *et al.*, CT694 and pgp3 as Serological Tools for Monitoring Trachoma Programs. *PLoS Negl. Trop. Dis.* **6**, e1873 (2012).
15. E. B. Goodhew, *et al.*, Longitudinal analysis of antibody responses to trachoma antigens before and after mass drug administration. *BMC Infect. Dis.* **14**, 3154 (2014).
16. B. F. Arnold, H. M. Scobie, J. W. Priest, P. J. Lammie, Integrated Serologic Surveillance of Population Immunity and Disease Transmission. *Emerg. Infect. Dis.* **24**, 1188–1194 (2018).
17. F. Liu, *et al.*, Short-term Forecasting of the Prevalence of Trachoma: Expert Opinion, Statistical Regression, versus Transmission Models. *PLoS Negl. Trop. Dis.* **9**, e0004000 (2015).
18. A. Pinsent, *et al.*, Probabilistic forecasts of trachoma transmission at the district level: A statistical model comparison. *Epidemics* **18**, 48–55 (2017).
19. D. M. Wittberg, *et al.*, WASH Upgrades for Health in Amhara (WUHA): study protocol for a cluster-randomised trial in Ethiopia. *BMJ Open* **11**, e039529 (2021).
20. World Health Organization, Trachoma (2020) (October 12, 2020).
21. J. D. Keenan, *et al.*, Slow resolution of clinically active trachoma following successful mass antibiotic treatments. *Arch. Ophthalmol. Chic. Ill 1960* **129**, 512–513 (2011).

22. D. R. Roberts, *et al.*, Cross-validation strategies for data with temporal, spatial, hierarchical,
or phylogenetic structure. *Ecography* **40**, 913–929 (2017).
23. D. L. Martin, *et al.*, The use of serology for trachoma surveillance: Current status and
priorities for future investigation. *PLoS Negl. Trop. Dis.* **14**, e0008316 (2020).
24. M.-G. Basáñez, *et al.*, A Research Agenda for Helminth Diseases of Humans: Modelling for
Control and Elimination. *PLoS Negl. Trop. Dis.* **6**, e1548 (2012).
25. A. Pinsent, M. Gambhir, Improving our forecasts for trachoma elimination: What else do we
need to know? *PLoS Negl. Trop. Dis.* **11**, e0005378 (2017).
26. Y. Shen, *et al.*, Modeling Approaches to Predicting Persistent Hotspots in SCORE Studies
for Gaining Control of Schistosomiasis Mansoni in Kenya and Tanzania. *J. Infect. Dis.* **221**,
796–803 (2020).
27. E. S. Nightingale, *et al.*, A spatio-temporal approach to short-term prediction of visceral
leishmaniasis diagnoses in India. *PLoS Negl. Trop. Dis.* **14**, e0008422 (2020).
28. S. D. Nash, *et al.*, Population-Based Prevalence of Chlamydia trachomatis Infection and
Antibodies in four Districts with Varying Levels of Trachoma Endemicity in Amhara, Ethiopia.
Am. J. Trop. Med. Hyg. (2020) https:/doi.org/10.4269/ajtmh.20-0777 (November 7, 2020).
29. A. Cama, *et al.*, Prevalence of signs of trachoma, ocular Chlamydia trachomatis infection
and antibodies to Pgp3 in residents of Kiritimati Island, Kiribati. *PLoS Negl. Trop. Dis.* **11**,
e0005863 (2017).
30. R. Butcher, *et al.*, Ocular Chlamydia trachomatis infection, anti-Pgp3 antibodies and
conjunctival scarring in Vanuatu and Tarawa, Kiribati before antibiotic treatment for
trachoma. *J. Infect.* **80**, 454–461 (2020).
31. J. S. Kim, *et al.*, Community-level chlamydial serology for assessing trachoma elimination in
trachoma-endemic Niger. *PLoS Negl. Trop. Dis.* **13** (2019).
32. S. K. West, B. Munoz, H. Mkocha, C. A. Gaydos, T. C. Quinn, The effect of Mass Drug
Administration for trachoma on antibodies to Chlamydia trachomatis pgp3 in children. *Sci.*
Rep. **10**, 15225 (2020).
33. D. L. Martin, *et al.*, Serology for Trachoma Surveillance after Cessation of Mass Drug
Administration. *PLoS Negl. Trop. Dis.* **9**, e0003555 (2015).
34. S. K. West, *et al.*, Can We Use Antibodies to Chlamydia trachomatis as a Surveillance Tool
for National Trachoma Control Programs? Results from a District Survey. *PLoS Negl. Trop.*
Dis. **10**, e0004352 (2016).
35. S. J. Migchelsen, *et al.*, Serology reflects a decline in the prevalence of trachoma in two
regions of The Gambia. *Sci. Rep.* **7**, 15040 (2017).
36. S. K. West, *et al.*, Surveillance Surveys for Reemergent Trachoma in Formerly Endemic
Districts in Nepal From 2 to 10 Years After Mass Drug Administration Cessation. *JAMA*
Ophthalmol. **135**, 1141 (2017).
37. S. J. Migchelsen, *et al.*, Defining Seropositivity Thresholds for Use in Trachoma Elimination
Studies. *PLoS Negl. Trop. Dis.* **11**, e0005230 (2017).
38. J. D. Keenan, *et al.*, Clinical Activity and Polymerase Chain Reaction Evidence of
Chlamydial Infection after Repeated Mass Antibiotic Treatments for Trachoma. *Am. J. Trop.*
Med. Hyg. **82**, 482–487 (2010).
39. A. Amza, *et al.*, Community-level Association between Clinical Trachoma and Ocular
Chlamydia Infection after MASS Azithromycin Distribution in a Mesoendemic Region of
Niger. *Ophthalmic Epidemiol.* **26**, 231–237 (2019).
40. A. M. Ramadhani, T. Derrick, D. Macleod, M. J. Holland, M. J. Burton, The Relationship
between Active Trachoma and Ocular Chlamydia trachomatis Infection before and after
Mass Antibiotic Treatment. *PLoS Negl. Trop. Dis.* **10**, e0005080 (2016).
41. S. D. Nash, *et al.*, Ocular Chlamydia trachomatis Infection Under the Surgery, Antibiotics,
Facial Cleanliness, and Environmental Improvement Strategy in Amhara, Ethiopia, 2011–
2015. *Clin. Infect. Dis.* **67**, 1840–1846 (2018).

42. A. C. A. Clements, *et al.*, Targeting Trachoma Control through Risk Mapping: The Example
of Southern Sudan. *PLoS Negl. Trop. Dis.* **4**, e799 (2010).
43. S. R. Polack, *et al.*, The household distribution of trachoma in a Tanzanian village: an
application of GIS to the study of trachoma. *Trans. R. Soc. Trop. Med. Hyg.* **99**, 218–225
(2005).
44. P. Diggle, S. Lophaven, Bayesian Geostatistical Design. *Scand. J. Stat.* **33**, 53–64 (2006).
45. J.-F. Schémann, *et al.*, Risk factors for trachoma in Mali. *Int. J. Epidemiol.*, 194–201 (2002).
46. B. Bero, *et al.*, Prevalence of and Risk Factors for Trachoma in Oromia Regional State of
Ethiopia: Results of 79 Population-Based Prevalence Surveys Conducted with the Global
Trachoma Mapping Project. *Ophthalmic Epidemiol.* **23**, 392–405 (2016).
47. Y.-H. Hsieh, L. D. Bobo, T. C. Quinn, S. K. West, Risk Factors for Trachoma: 6-Year Follow-
up of Children Aged 1 and 2 Years. *Am. J. Epidemiol.* **152**, 204–211 (2000).
48. I. Phiri, *et al.*, The Burden of and Risk Factors for Trachoma in Selected Districts of
Zimbabwe: Results of 16 Population-Based Prevalence Surveys. *Ophthalmic Epidemiol.* **25**,
181–191 (2018).
49. W. Alemayehu, M. Melese, E. Fredlander, A. Worku, P. Courtright, Active trachoma in
children in central Ethiopia: association with altitude. *Trans. R. Soc. Trop. Med. Hyg.* **99**,
840–843 (2005).
50. R. F. Baggaley, *et al.*, Distance to water source and altitude in relation to active trachoma in
Rombo district, Tanzania. *Trop. Med. Int. Health TM IH* **11**, 220–227 (2006).
51. J. Ngondi, *et al.*, Risk factors for active trachoma in children and trichiasis in adults: a
household survey in Amhara Regional State, Ethiopia. *Trans. R. Soc. Trop. Med. Hyg.* **102**,
432–438 (2008).
52. E. M. Harding-Esch, *et al.*, Trachoma Prevalence and Associated Risk Factors in The
Gambia and Tanzania: Baseline Results of a Cluster Randomised Controlled Trial. *PLoS*
Negl. Trop. Dis. **4**, e861 (2010).
53. M. M. Mesfin, *et al.*, A Community-Based Trachoma Survey: Prevalence and Risk Factors in
the Tigray Region of Northern Ethiopia. *Ophthalmic Epidemiol.* **13**, 173–181 (2006).
54. C. Mpyet, B. D. Lass, H. B. Yahaya, A. W. Solomon, Prevalence of and Risk Factors for
Trachoma in Kano State, Nigeria. *PLOS ONE* **7**, e40421 (2012).
55. C. Mpyet, M. Goyol, C. Ogoshi, Personal and environmental risk factors for active trachoma
in children in Yobe state, north-eastern Nigeria. *Trop. Med. Int. Health* **15**, 168–172 (2010).
56. J.-F. Schémann, *et al.*, Trachoma, flies and environmental factors in Burkina Faso. *Trans.*
R. Soc. Trop. Med. Hyg. **97**, 63–68 (2003).
57. C. Vinke, S. Lonergan, Social and environmental risk factors for trachoma: a mixed methods
approach in the Kembata Zone of southern Ethiopia. *Can. J. Dev. Stud. Can. Détudes Dév.*
32, 254–268 (2011).
58. T. Edwards, *et al.*, Risk factors for active trachoma and Chlamydia trachomatis infection in
rural Ethiopia after mass treatment with azithromycin. *Trop. Med. Int. Health* **13**, 556–565
(2008).
59. A. Abdou, *et al.*, Prevalence and risk factors for trachoma and ocular Chlamydia trachomatis
infection in Niger. *Br. J. Ophthalmol.* **91**, 13–17 (2007).
60. A. R. Last, *et al.*, Risk Factors for Active Trachoma and Ocular Chlamydia trachomatis
Infection in Treatment-Naïve Trachoma-Hyperendemic Communities of the Bijagós
Archipelago, Guinea Bissau. *PLoS Negl. Trop. Dis.* **8**, e2900 (2014).
61. X. Chen, W. D. Nordhaus, VIIRS Nighttime Lights in the Estimation of Cross-Sectional and
Time-Series GDP. *Remote Sens.* **11**, 1057 (2019).
62. B. Thylefors, C. R. Dawson, B. R. Jones, S. K. West, H. R. Taylor, A simple system for the
assessment of trachoma and its complications. *Bull. World Health Organ.* **65**, 477–483
(1987).
63. J. K. Møller, L. N. Pedersen, K. Persson, Comparison of the Abbott RealTime CT New

659   Formulation Assay with Two Other Commercial Assays for Detection of Wild-Type and New
660   Variant Strains of Chlamydia trachomatis. *J. Clin. Microbiol.* **48**, 440–443 (2010).

661 64. A. Cheng, Q. Qian, J. E. Kirby, Evaluation of the Abbott RealTime CT/NG Assay in
662   Comparison to the Roche Cobas Amplicor CT/NG Assay ▽. *J. Clin. Microbiol.* **49**, 1294–
663   1300 (2011).

664 65. K. J. Ray, *et al.*, Estimating Community Prevalence of Ocular *Chlamydia trachomatis*
665   Infection using Pooled Polymerase Chain Reaction Testing. *Ophthalmic Epidemiol.* **21**, 86–
666   91 (2014).

667 66. S. C. Woodhall, *et al.*, Advancing the public health applications of Chlamydia trachomatis
668   serology. *Lancet Infect. Dis.* **18**, e399–e407 (2018).

669 67. Central Statistics Agency (CSA), Regional Bureau of Finance and Economic Development
670   (BoFED), *Ethiopia - Subnational Administrative Divisions* (2020) (November 3, 2020).

671 68. P. J. Diggle, P. J. Ribiero Jr, *Model-Based Geostatistics*, 1st ed (Springer Series in
672   Statistics, 2007).

673 69. C. Funk, *et al.*, The climate hazards infrared precipitation with stations—a new
674   environmental record for monitoring extremes. *Sci. Data* **2**, 150066 (2015).

675 70. J. T. Abatzoglou, S. Z. Dobrowski, S. A. Parks, K. C. Hegewisch, TerraClimate, a high-
676   resolution global dataset of monthly climate and climatic water balance from 1958–2015.
677   *Sci. Data* **5**, 170191 (2018).

678 71. K. Didan, *MOD13Q1 MODIS/Terra Vegetation Indices 16-Day L3 Global 250m SIN Grid
679   V006 [Data set]* (NASA EOSDIS Land Processes DAAC, 2015).

680 72. A. Jarvis, H. Reuter, A. Nelson, E. Guevara, *Hole-filled SRTM for the globe Version 4,
681   available from the CGIAR-CSI SRTM 90m* (2008).

682 73. J.-F. Pekel, A. Cottam, N. Gorelick, A. S. Belward, High-resolution mapping of global
683   surface water and its long-term changes. *Nature* **540**, 418–422 (2016).

684 74. T. G. Tiecke, *et al.*, Mapping the world population one building at a time. *ArXiv171205839
685   Cs* (2017) (October 1, 2020).

686 75. OpenStreetMap contributors, *Planet dump retrieved from https://planet.osm.org* (2017)
687   (March 5, 2021).

688 76. C. D. Elvidge, K. Baugh, M. Zhizhin, F. C. Hsu, T. Ghosh, VIIRS night-time lights. *Int. J.
689   Remote Sens.* **38**, 5860–5879 (2017).

690 77. D. J. Weiss, *et al.*, Global maps of travel time to healthcare facilities. *Nat. Med.* (2020)
691   https:/doi.org/10.1038/s41591-020-1059-1 (November 18, 2020).

692 78. N. Gorelick, *et al.*, Google Earth Engine: Planetary-scale geospatial analysis for everyone.
693   *Remote Sens. Environ.* (2017) https:/doi.org/10.1016/j.rse.2017.06.031.

694 79. C. E. Rasmussen, C. K. I. Williams, *Gaussian processes for machine learning* (MIT Press,
695   2006).

696 80. L. Breiman, Stacked regressions. *Mach. Learn.* **24**, 49–64 (1996).

697 81. D. H. Wolpert, Stacked generalization. *Neural Netw.* **5**, 241–259 (1992).

698 82. M. J. van der Laan, E. C. Polley, A. E. Hubbard, Super Learner (2007) (November 25,
699   2020).

700 83. T. Hastie, R. Tibshirani, Generalized Additive Models. *Stat. Sci.* **1**, 297–310 (1986).

701 84. L. Breiman, Random Forests (September 19, 2020).

702 85. J. H. Friedman, Greedy Function Approximation: A Gradient Boosting Machine. *Ann. Stat.*
703   **29**, 1189–1232 (2001).

704 86. J. H. Friedman, Multivariate Adaptive Regression Splines. *Ann. Stat.* **19**, 1–67 (1991).

705 87. P. Ploton, *et al.*, Spatial validation reveals poor predictive performance of large-scale
706   ecological mapping models. *Nat. Commun.* **11**, 4540 (2020).

707 88. T. O. Kvålseth, Cautionary Note about R^2. *Am. Stat.* **39**, 279–285 (1985).

708 89. A. E. Hubbard, S. Kherad-Pajouh, M. J. van der Laan, Statistical Inference for Data
709   Adaptive Target Parameters. *Int. J. Biostat.* **12**, 3–19 (2016).

90. D. Benkeser, *et al.*, A machine learning-based approach for estimating and testing
associations with multivariate outcomes. *Int. J. Biostat.* **0** (2020).
91. P. H. Hiemstra, E. J. Pebesma, C. J. W. Twenhofel, G. B. M. Heuvelink, Real-time
automatic interpolation of ambient gamma dose rates from the Dutch Radioactivity
Monitoring Network. *Comput. Geosci.* (2008).
92. C. Aybar, Q. Wu, L. Bautista, R. Yali, A. Barja, rgee: An R package for interacting with
Google Earth Engine. *J. Open Source Softw.* (2020).
93. J. Friedman, T. Hastie, R. Tibshirani, Regularization Paths for Generalized Linear Models
via Coordinate Descent. *J. Stat. Softw.* **33**, 1–22 (2010).
94. F. Rousset, J.-B. Ferdy, Testing environmental and genetic effects in the presence of spatial
autocorrelation. *Ecography* **37**, 781–790 (2014).
95. J. R. Coyle, N. S. Hejazi, I. Malenica, O. Sofrygin, *sl3: Modern Pipelines for Machine
Learning and Super Learning* (2021) https:/doi.org/10.5281/zenodo.1342293.
96. R. Valavi, J. Elith, J. J. Lahoz-Monfort, G. Guillera-Arroita, blockCV: An r package for
generating spatially or environmentally separated folds for k-fold cross-validation of species
distribution models. *Methods Ecol. Evol.* **10**, 225–232 (2019).
97. R Core Team, *R: A language and environment for statistical computing.* (R Foundation for
Statistical Computing, 2020).